Matching articles for "Repatha Pushtronex"

Reduction of Cardiovascular Risk with Evolocumab (Repatha)

   
The Medical Letter on Drugs and Therapeutics • April 24, 2017;  (Issue 1519)
The results of the recently published FOURIER trial have shown a reduction in cardiovascular events with addition of the PCSK9 inhibitor evolocumab (Repatha) to statin therapy in patients with...
The results of the recently published FOURIER trial have shown a reduction in cardiovascular events with addition of the PCSK9 inhibitor evolocumab (Repatha) to statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD).
Med Lett Drugs Ther. 2017 Apr 24;59(1519):63-4 | Show Full IntroductionHide Full Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • October 24, 2016;  (Issue 1506)
Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment...
Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment of most patients who require lipid-lowering therapy.
Med Lett Drugs Ther. 2016 Oct 24;58(1506):133-40 | Show Full IntroductionHide Full Introduction

In Brief: Repatha Pushtronex - A New Evolocumab Injection Device

   
The Medical Letter on Drugs and Therapeutics • September 12, 2016;  (Issue 1503)
The PCSK9 inhibitor evolocumab (Repatha – Amgen) is now available in a single-dose, hands-free device (Repatha Pushtronex) for once-monthly subcutaneous infusion. Evolocumab is FDA-approved as an adjunct to...
The PCSK9 inhibitor evolocumab (Repatha – Amgen) is now available in a single-dose, hands-free device (Repatha Pushtronex) for once-monthly subcutaneous infusion. Evolocumab is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C), and as an adjunct to diet and other LDL-lowering therapies for patients with homozygous familial hypercholesterolemia (HoFH).

Evolocumab is also available in 140-mg single-use prefilled syringes and autoinjectors (Repatha Sureclick).1 Use of these formulations to administer the once-monthly dose (420 mg) requires patients to inject themselves three consecutive times within 30 minutes. Another PCSK9 inhibitor, alirocumab (Praluent), is injected every 2 weeks; it is available in single-dose prefilled syringes and pens.

The Repatha Pushtronex system consists of a single-use, battery-powered infusor and a prefilled cartridge containing a 420-mg dose of evolocumab. Once assembled, the patient adheres the device to the skin of the abdomen, thigh, or upper arm and presses a button to begin the subcutaneous injection; infusion of the dose takes about 9 minutes. One Repatha Pushtronex device costs $1175. Three 140-mg Repatha Sureclick autoinjectors or Repatha prefilled syringes cost $1627.2

  1. Evolocumab (Repatha) – a second PCSK9 inhibitor to lower LDL-cholesterol. Med Lett Drugs Ther 2015; 57:140.
  2. Approximate WAC for one 420-mg dose. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. August 5, 2016. Reprinted with permission by First Databank, Inc. All rights reserved. ©2016. www.fdbhealth.com/policies/drug-pricing-policy.


Download complete U.S. English article

Med Lett Drugs Ther. 2016 Sep 12;58(1503):120 | Show Full IntroductionHide Full Introduction